HER-2 positive

Age ≥ 50 years, HER2 IHC3+, dual HER2 blockade, and high PLR independently predict pCR in patients with HER2+ breast cancer. The nomogram provides a clinically applicable tool for pCR prediction, which may aid in optimizing personalized NAC strategies for this population.

In summary, endometrial carcinomas with a somatically derived yolk sac tumor component are highly aggressive, predominantly p53-abnormal, with smaller subsets classified as MMRd or NSMP. Recognition of the YST component is crucial, and biomarker profiling may reveal therapeutic targets.

This review explores recent research progress in immunotherapy for gastric cancer with specific molecular subtypes, including HER2-positive, Claudin18.2-positive, dMMR/MSI-H, Epstein-Barr virus (EBV)-positive, and alpha-fetoprotein (AFP)-positive subtypes. The aim is to provide insights for developing personalized and precise treatment strategies for gastric cancer patients with different molecular subtypes and clinical stages.

P1, N=20, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P=N/A, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026

P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center

Patients with lymph node metastasis (13%) were significantly higher than those without lymph node metastasis (4.66%), and the difference was statistically significant (P <.01). The research data indicate that correlation between the expression of HER2 in areas with a high incidence of gastric cancer and the pathological characteristics.

In ER-positive, HER2-positive breast cancer, negative or weak PR expression was associated with inferior DFS and DRFS compared to strong PR expression. These findings highlight the potential prognostic value of PR status in this group, underscoring its relevance in guiding treatment and follow-up strategies for more individualized patient care.

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, abemaciclib, dalpiciclib) combined with endocrine therapy (ET) were a major advance in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) worldwide...However, clinical development of CDK4/6i in HER2+ MBC slowed, given the advent of highly effective tyrosine-kinase inhibitors (TKIs) (i.e., tucatinib) and antibody-drug conjugates (ADCs) (i.e., trastuzumab deruxtecan), which currently dominate the treatment armamentarium...Subsequently, the phase III PATINA trial (which included patients with 1L HR+HER2+ MBC, treated with palbociclib vs. placebo with maintenance ET+ H&lsqb;P]) noted a striking PFS improvement of >15 months in the palbociclib arm, renewing interest in CDK4/6i-based treatments for HR+HER2+ MBC. Herein, we review the development of CDK4/6i in HER2+ BC, discussing current challenges and potential future directions.

Findings in the neoadjuvant pCR cohort were imprecise and hypothesis-generating. Given the retrospective registry design, lack of recurrence-specific endpoints, and potential residual confounding, results should not be interpreted as causal but support continued RT use outside prospective de-escalation trials.

By integrating data from clinical trials, molecular analyses, and patent landscapes, this review illustrates how multimechanistic, biomarker-guided therapies supported by advanced drug-delivery technologies are redefining contemporary precision oncology in breast cancer. The emerging therapeutic paradigm underscores the convergence of targeted therapy, immunomodulation, synthetic lethality, and localized immune-activating approaches, charting a path toward further personalization of treatment in the years ahead.

P1, N=18, Not yet recruiting, Beijing Immunochina Medical Science & Technology Co., Ltd.